Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla (Levonorgestrel and Ethinyl Estradiol) Transdermal System
August 20, 2021 at 07:30 am EDT
Share
Agile Therapeutics, Inc. announced a partnership with Pandia Health, an online telehealth service, which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in a fast-growing channel. Pandia Health offers convenient prescription fulfillment for women with active birth control prescriptions, as well as access to expert birth control doctors who can provide prescriptions through asynchronous online visits. All patients receive free delivery of their birth control. The Company and Pandia plan to phase in the availability of Twirla in the second half of 2021. The use of telehealth in contraceptive care has grown over the past several years and has come into the spotlight during the COVID-19 pandemic. A recent article in the reproductive health journal Contraception examined trends in how women accessed contraceptive care during the COVID-19 pandemic, finding a decrease for in-person visits and a subsequent increase in the use of telehealth. A 2020 report by the Guttmacher Institute found that 24% of women using the pill reported that, because of the pandemic, they had switched to a telemedicine appointment with their health care provider to have their prescription refilled.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla (Levonorgestrel and Ethinyl Estradiol) Transdermal System